<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04870073</url>
  </required_header>
  <id_info>
    <org_study_id>RAPPER-MAN_2021</org_study_id>
    <nct_id>NCT04870073</nct_id>
  </id_info>
  <brief_title>Retrograde Autologous Priming and Mannitol for Reducing Hemodilution in Cardiac Surgery</brief_title>
  <acronym>RAPPER-MAN</acronym>
  <official_title>Retrograde Autologous Priming for Preserving Hemoglobin Peri-operatively With or Without Mannitol: A Pilot Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hamilton Health Sciences Corporation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>McMaster University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Hamilton Health Sciences Corporation</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Hemodilution reduces concentrations of blood constituents: concentration of hemoglobin, red&#xD;
      blood cells (hematocrit), physiological ions and coagulation factors that can contribute to&#xD;
      impaired hemostasis and increasing the risk of perioperative blood transfusions. This pilot&#xD;
      study will assess the feasibility of a large RCT to evaluate 2 techniques for reducing&#xD;
      hemodilution during cardiac surgery: 1) retrograde autologous priming and 2) intraoperative&#xD;
      mannitol. The aim of this pilot trial is to demonstrate feasibility of a larger trial to&#xD;
      evaluate whether retrograde autologous priming and/or mannitol are superior to conventional&#xD;
      priming alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The use of large volumes of artificial priming fluids is still very high in cardiac surgery&#xD;
      for routine CABG surgery with cardiopulmonary bypass. The resulting hemodilution is&#xD;
      deleterious for patients and often requires counter measures to maintain fluid balance during&#xD;
      and after surgery. Retrograde autologous priming and mannitol are simple low-cost solutions&#xD;
      to the problem of hemodilution but their effectiveness, either alone or in combination, is&#xD;
      unclear due to a lack of high-quality evidence. RAPPER-MAN is a single-centre 2x2 factorial&#xD;
      cluster randomized trial. Participants will be randomly assigned (1:1:1:1 ratio) to the&#xD;
      intervention groups: 1) Retrograde autologous priming (≥600 mL) + mannitol (0.3 g/kg bolus),&#xD;
      2) Retrograde autologous priming (≥600 mL) alone, 3) Conventional priming + mannitol (0.3&#xD;
      g/kg bolus), and 4) Conventional priming alone. The primary outcome is the change in&#xD;
      hemoglobin concentration during cardiopulmonary bypass. Retrograde autologous priming will be&#xD;
      performed within 10 minutes before, and mannitol will be added to the venous reservoir of the&#xD;
      CPB machine within 5 minutes before, the start of cardiopulmonary bypass. The results of the&#xD;
      larger trial are expected to have broad implications for fluid management in cardiac surgery&#xD;
      in Canada.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2021</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">February 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>single-centre, single blinded, 2x2 factorial, cluster randomized trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Feasibility Outcomes</measure>
    <time_frame>Start to end of study recruitment, which is anticipated to take 20 weeks</time_frame>
    <description>Feasibility will be established in the pilot phase if all the following criteria are met:&#xD;
Average recruitment rate of 7 patients per week.&#xD;
Complete Hb data before and after cardiopulmonary bypass in 90% of patients.&#xD;
Compliance of the research team members, OR staff and ward medical staff with the protocol of 90%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in hemoglobin concentration during cardiopulmonary bypass</measure>
    <time_frame>Start to end of cardiopulmonary bypass</time_frame>
    <description>Change in arterial hemoglobin concentration during cardiopulmonary bypass</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in hemoglobin concentration after cardiopulmonary bypass</measure>
    <time_frame>Start of cardiopulmonary bypass to hospital discharge or 5 days maximum (whichever occurs first)</time_frame>
    <description>Change in arterial hemoglobin concentration from baseline to discharge</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Blood transfusion</measure>
    <time_frame>Start of surgery to hospital discharge or 5 days maximum (whichever occurs first)</time_frame>
    <description>Proportion of patients experiencing red blood cell transfusion</description>
  </other_outcome>
  <other_outcome>
    <measure>Change in oxygen consumption during cardiopulmonary bypass</measure>
    <time_frame>Start to end of cardiopulmonary bypass</time_frame>
    <description>Change in oxygen consumption during cardiopulmonary bypass</description>
  </other_outcome>
  <other_outcome>
    <measure>Autologous prime volume</measure>
    <time_frame>Within 10 minutes before cardiopulmonary bypass</time_frame>
    <description>Total prime volume removed from the extracorporeal circuit during the retrograde autologous priming procedure</description>
  </other_outcome>
  <other_outcome>
    <measure>Hyponatremia</measure>
    <time_frame>Before and 24 hours after surgery</time_frame>
    <description>Sodium concentration of less than 135 mmol/L (135 mEq/L)</description>
  </other_outcome>
  <other_outcome>
    <measure>Diuresis</measure>
    <time_frame>Within 24 hours of surgery</time_frame>
    <description>Total volume of urine within 24 hours of surgery</description>
  </other_outcome>
  <other_outcome>
    <measure>Hemofiltration use</measure>
    <time_frame>During cardiopulmonary bypass</time_frame>
    <description>Proportion of patients undergoing hemofiltration</description>
  </other_outcome>
  <other_outcome>
    <measure>Fluid balance</measure>
    <time_frame>Daily in ICU from admission to hospital discharge or 5 days maximum (whichever occurs first)</time_frame>
    <description>Net fluid balance (intake minus output) calculated using a cumulative fluid chart</description>
  </other_outcome>
  <other_outcome>
    <measure>Acute kidney injury</measure>
    <time_frame>Start of surgery to hospital discharge or 5 days maximum (whichever occurs first)</time_frame>
    <description>Acute kidney injury as measured by peak postoperative creatinine and KDIGO</description>
  </other_outcome>
  <other_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>Time from admission to hospital discharge or 5 days maximum (whichever occurs first)</time_frame>
    <description>Length of hospital stay (days)</description>
  </other_outcome>
  <other_outcome>
    <measure>Major adverse cardiovascular events</measure>
    <time_frame>Start of surgery to hospital discharge or 5 days maximum (whichever occurs first)</time_frame>
    <description>Composite outcome of cardiovascular death, non-fatal myocardial infarction or stroke</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Hemodilution</condition>
  <condition>Coronary Artery Disease</condition>
  <condition>Fluid Overload</condition>
  <arm_group>
    <arm_group_label>Retrograde autologous priming + mannitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Retrograde autologous priming alone</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional priming + mannitol</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants will receive conventional priming. In addition, mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Conventional priming alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants will receive conventional priming alone.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Retrograde autologous priming</intervention_name>
    <description>Priming solution (≥600 mL) will be removed from the extracorporeal circuit within 10 minutes before the initiation of cardiopulmonary bypass. Priming solution may be removed from 3 locations within the extracorporeal circuit (i.e. arterial, venous and cardioplegia lines) as determined by the perfusionist team.</description>
    <arm_group_label>Retrograde autologous priming + mannitol</arm_group_label>
    <arm_group_label>Retrograde autologous priming alone</arm_group_label>
    <other_name>RAP</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mannitol</intervention_name>
    <description>Mannitol will be added as a bolus (0.3 g/kg) to the venous reservoir of the cardiopulmonary bypass machine within 5 min before the start of cardiopulmonary bypass.</description>
    <arm_group_label>Conventional priming + mannitol</arm_group_label>
    <arm_group_label>Retrograde autologous priming + mannitol</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Priming</intervention_name>
    <description>The conventional priming procedure will be used in the standardized cardiopulmonary machine used at the Hamilton General Hospital.</description>
    <arm_group_label>Conventional priming + mannitol</arm_group_label>
    <arm_group_label>Conventional priming alone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. ≥18 years of age.&#xD;
&#xD;
          2. Undergoing a first-time cardiac surgical procedure (i.e. isolated CABG, isolated&#xD;
             single cardiac valve surgery or a combination of both or isolated ascending aorta&#xD;
             replacement) with the use of cardiopulmonary bypass (CPB) and median sternotomy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Left ventricle ejection fraction &lt;25%&#xD;
&#xD;
          2. Emergency surgery&#xD;
&#xD;
          3. History of bleeding disorder&#xD;
&#xD;
          4. Inherited thromboembolic or infective endocarditis (active)&#xD;
&#xD;
          5. Previous cardiac surgery&#xD;
&#xD;
          6. Severe renal impairment (serum creatinine &gt;250 μmol/L)&#xD;
&#xD;
          7. Hemoglobin &lt;80 g/L&#xD;
&#xD;
          8. Thrombocytopenia (&lt;50,000 platelets per μL)&#xD;
&#xD;
          9. Expected circulatory arrest&#xD;
&#xD;
         10. Body weight ≤50 kg&#xD;
&#xD;
         11. Allergy to mannitol&#xD;
&#xD;
         12. Pregnancy or breast feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andre Lamy, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hamilton Health Sciences Corporation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Austin Browne, PhD</last_name>
    <phone>19052973479</phone>
    <phone_ext>40582</phone_ext>
    <email>Austin.Browne@phri.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Andre Lamy, MD</last_name>
    <email>lamya@mcmaster.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hamilton General Hospital</name>
      <address>
        <city>Hamilton</city>
        <state>Ontario</state>
        <zip>L8L 2X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <reference>
    <citation>Hensley NB, Gyi R, Zorrilla-Vaca A, Choi CW, Lawton JS, Brown CH 4th, Frank SM, Grant MC, Cho BC. Retrograde Autologous Priming in Cardiac Surgery: Results From a Systematic Review and Meta-analysis. Anesth Analg. 2021 Jan;132(1):100-107. doi: 10.1213/ANE.0000000000005151.</citation>
    <PMID>32947294</PMID>
  </reference>
  <reference>
    <citation>Ljunggren M, Sköld A, Dardashti A, Hyllén S. The use of mannitol in cardiopulmonary bypass prime solution-Prospective randomized double-blind clinical trial. Acta Anaesthesiol Scand. 2019 Nov;63(10):1298-1305. doi: 10.1111/aas.13445. Epub 2019 Jul 29.</citation>
    <PMID>31287556</PMID>
  </reference>
  <reference>
    <citation>Task Force on Patient Blood Management for Adult Cardiac Surgery of the European Association for Cardio-Thoracic Surgery (EACTS) and the European Association of Cardiothoracic Anaesthesiology (EACTA), Boer C, Meesters MI, Milojevic M, Benedetto U, Bolliger D, von Heymann C, Jeppsson A, Koster A, Osnabrugge RL, Ranucci M, Ravn HB, Vonk ABA, Wahba A, Pagano D. 2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. J Cardiothorac Vasc Anesth. 2018 Feb;32(1):88-120. doi: 10.1053/j.jvca.2017.06.026. Epub 2017 Sep 30. Review.</citation>
    <PMID>29029990</PMID>
  </reference>
  <reference>
    <citation>Trapp C, Schiller W, Mellert F, Halbe M, Lorenzen H, Welz A, Probst C. Retrograde Autologous Priming as a Safe and Easy Method to Reduce Hemodilution and Transfusion Requirements during Cardiac Surgery. Thorac Cardiovasc Surg. 2015 Oct;63(7):628-34. doi: 10.1055/s-0035-1548731. Epub 2015 Mar 24.</citation>
    <PMID>25803120</PMID>
  </reference>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>April 20, 2021</study_first_submitted>
  <study_first_submitted_qc>April 29, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 3, 2021</study_first_posted>
  <last_update_submitted>April 29, 2021</last_update_submitted>
  <last_update_submitted_qc>April 29, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hamilton Health Sciences Corporation</investigator_affiliation>
    <investigator_full_name>Andre Lamy</investigator_full_name>
    <investigator_title>Cardiac Surgeon</investigator_title>
  </responsible_party>
  <keyword>retrograde autologous priming</keyword>
  <keyword>mannitol</keyword>
  <keyword>cardiopulmonary bypass</keyword>
  <keyword>cardiac surgery</keyword>
  <keyword>hemodilution</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mannitol</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

